VANDERBILT UNIVERSITY MEDICAL CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1925-01-01

Employees: 10K

Market Cap: -

Website: http://www.vumc.org

Clinical Trials

Prospective Observation of Cardiac Safety With Proteasome Inhibition

Completed

Conditions: Heart Failure
Multiple Myeloma

First Posted Date: 2014-07-01

Last Posted Date: 2020-09-14

Lead Sponsor: Vanderbilt University Medical Center

Target Recruit Count: 95

Registration Number: NCT02178579

Locations: 🇺🇸
University of Pennsylvania/Smilow Center for Translational Research, Philadelphia, Pennsylvania, United States
🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

Effect of Prolonged PDE-5 Inhibition on Insulin Signaling in Skeletal Muscle.

Phase 4

Completed

Conditions: Metabolic Syndrome

Interventions: Drug: Sildenafil citrate
Drug: Placebo Oral Capsule

First Posted Date: 2014-05-02

Last Posted Date: 2017-04-19

Lead Sponsor: Vanderbilt University Medical Center

Target Recruit Count: 15

Registration Number: NCT02129725

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

Obesity Surgery and Kidney Transplant for Patients With Obesity and Renal Failure

Not Applicable

Active, not recruiting

Conditions: Severe Obesity
Renal Failure

Interventions: Procedure: Gastric Bypass
Other: Weight Loss Program

First Posted Date: 2014-05-01

Last Posted Date: 2024-02-13

Lead Sponsor: Vanderbilt University Medical Center

Target Recruit Count: 75

Registration Number: NCT02128802

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

Metabolic and Cardiovascular Impact of CD36 Deficiency in African Americans

Completed

Conditions: Obesity

First Posted Date: 2014-04-30

Last Posted Date: 2016-12-30

Lead Sponsor: Vanderbilt University Medical Center

Target Recruit Count: 21

Registration Number: NCT02126735

Locations: 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States

Endogenous Renin-Angiotensin-Aldosterone System and Glucose Metabolism

Phase 4

Completed

Conditions: Metabolic Syndrome

Interventions: Other: Low Salt diet plus Placebo tablet
Drug: Epleronone
Other: Low Sodium diet plus Salt tablet
Drug: Amlodipine

First Posted Date: 2014-01-13

Last Posted Date: 2021-01-20

Lead Sponsor: Vanderbilt University Medical Center

Target Recruit Count: 44

Registration Number: NCT02034435

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

Modafinil and Cognitive Function in POTS

Early Phase 1

Active, not recruiting

Conditions: Postural Tachycardia Syndrome

Interventions: Drug: Placebo
Drug: Modafinil
Drug: Propranolol

First Posted Date: 2013-11-20

Last Posted Date: 2025-01-10

Lead Sponsor: Vanderbilt University Medical Center

Target Recruit Count: 20

Registration Number: NCT01988883

Locations: 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States

Prospective Randomized Evaluation of an Ultra Conservative Approach to Implantable Defibrillator (ICD) Programming in Patients With a Left Ventricular Assist Device (LVAD).

Not Applicable

Completed

Conditions: Heart Failure

Interventions: Other: Ultra Conservative ICD Programming
Other: Traditional ICD Programming

First Posted Date: 2013-11-07

Last Posted Date: 2017-08-16

Lead Sponsor: Vanderbilt University Medical Center

Target Recruit Count: 80

Registration Number: NCT01977703

Locations: 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States

Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism

Phase 4

Completed

Conditions: Atrial Flutter
Atrial Fibrillation

Interventions: Drug: dabigatran etexilate mesylate

First Posted Date: 2013-11-05

Last Posted Date: 2017-09-12

Lead Sponsor: Vanderbilt University Medical Center

Target Recruit Count: 101

Registration Number: NCT01976507

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia

Phase 2

Completed

Conditions: Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)

Interventions: Drug: Montelukast added to Hydroxyurea
Drug: Placebo added to Hydroxyurea

First Posted Date: 2013-10-10

Last Posted Date: 2019-03-26

Lead Sponsor: Vanderbilt University Medical Center

Target Recruit Count: 46

Registration Number: NCT01960413

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Seizure Prophylaxis With Levetiracetam in Aneurysmal Subarachnoid Hemorrhage - Pilot Study

Phase 4

Withdrawn

Conditions: Subarachnoid Hemorrhage
Seizures

Interventions: Drug: levetiracetam

First Posted Date: 2013-09-05

Last Posted Date: 2017-11-01

Lead Sponsor: Vanderbilt University Medical Center

Registration Number: NCT01935908

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy